Jazz Pharmaceuticals plc is a global biopharmaceutical firm dedicated to discovering, advancing, and bringing to market innovative medicines for conditions where treatment options are lacking, serving patients across the United States, Europe, and other international regions. Its extensive portfolio of both commercialized therapies and development candidates primarily focuses on neuroscience, particularly sleep disorders and movement conditions, alongside oncology, addressing both hematologic (blood) cancers and solid tumors. Among its principal marketed products are Xyrem, an oral solution managing cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients aged seven and older; Sunosi, also for EDS but in individuals with narcolepsy and obstructive sleep apnea; Erwinaze, targeting acute lymphoblastic leukemia; Defitelio, which treats hepatic veno-occlusive disease in adults and children; Vyxeos liposome for injection, indicated for adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca, prescribed for adult patients with metastatic small cell lung cancer. The company's developmental pipeline features Xywav, an oxybate candidate intended for EDS and cataplexy linked to narcolepsy, as well as idiopathic hypersomnia; JZP-324, a low-sodium oxybate formulation aiming to offer a significant alternative for narcolepsy patients; JZP385, a T-type calcium channel modulator being explored for essential tremor; JZP458, a recombinant Erwinia asparaginase used in multi-agent chemotherapy for both pediatric and adult patients; and JZP150, a compound under investigation for post-traumatic stress disorder. Jazz Pharmaceuticals maintains strategic licensing and collaborative partnerships with entities such as ImmunoGen, Inc., Codiak BioSciences, Inc., Pfenex, Inc., XL-protein GmbH, and Redx Pharma plc. Established in 2003, Jazz Pharmaceuticals plc operates from its headquarters in Dublin, Ireland.
